卷 22, 编号 4 (2020) |
CLINICAL ONCOLOGY |
Interim results of a multicenter retrospective-prospective observational post-marketing study of Extimia® BIOCAD (INN: empegfilgrastim) to evaluate safety and efficacy in patients with lymphoproliferative diseases receiving cytotoxic therapy |
(Rus)
|